OASMY (Vivesto AB) Research & Development: $0.00 Mil (TTM As of Mar. 2026)

What is Vivesto AB Research & Development?

Vivesto AB OASMY 26 Research & Development is $0.00 Mil as of Mar. 2026. GuruFocus rates OASMY with a GF Score™ of 26/100. The stock has 1 warning sign investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Vivesto AB's Research & Development for the three months ended in Mar. 2026 was $0.00 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was $0.00 Mil.

Vivesto AB (OTCPK:OASMY) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Vivesto AB Research & Development Related Terms

Vivesto AB Research & Development Historical Data

* Premium members only.

The historical data trend for Vivesto AB's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vivesto AB Research & Development Chart

Vivesto AB Annual Data

Trend

Apr16

Apr17

Apr18

Apr19

Apr20

Dec21

Dec22

Dec23

Dec24

Dec25

Research & Development

Get a 7-Day Free Trial

0.00

Vivesto AB Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
Research & Development	Get a 7-Day Free Trial															0.00	0.00	0.00	0.00	0.00

26GF Score

Vivesto AB OASMY

Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Vivesto AB Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Frequently Asked Questions Learn more about Research & Development →

What does a Research & Development of $0.00 Mil mean?

Vivesto AB (OASMY) has a Research & Development of $0.00 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Vivesto AB and its competitors.

Is Vivesto AB's Research & Development too high?

Vivesto AB's current Research & Development is $0.00 Mil. Overall, Vivesto AB has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.

How does Vivesto AB's Research & Development compare to ZTS and UTHR?

Vivesto AB's Research & Development of $0.00 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Research & Development for a Drug Manufacturers company?

A good Research & Development depends on the Drug Manufacturers industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Research & Development mean?

A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Vivesto AB and its competitors. Vivesto AB's current Research & Development is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Vivesto AB stock overvalued right now?

Vivesto AB (OASMY) has a current Research & Development of $0.00 Mil. The current Research & Development is $0.00 Mil. Vivesto AB's overall GF Score™ is 26/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Research & Development calculated?

Research & Development is calculated from a company's financial statements. For Vivesto AB (OASMY), the current Research & Development is $0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Vivesto AB Business Description

Industry Healthcare Drug Manufacturers

Comparable Companies XSAT:ACUC OSTO:NEWBRY XSAT:ODI XSAT:PMED OSTO:GABA OSTO:ERMA OSTO:KLAR OSTO:MOB XTER:MRK XSWX:GALD TSE:4502 SHSE:600276 NSE:SUNPHARMA LSE:HLN XTAE:TEVA XSWX:SDZ ZTS UTHR HKSE:03692 VTRS

Other Exchanges VIVE:Sweden OMA:Germany

Address Gustav III:s Boulevard 46, 5th Floor, Solna, SWE, SE-169 73

Website https://www.vivesto.com

Vivesto AB is a research and development company that develops new treatment options for patients suffering from difficult-to-treat cancer. The company's product development leverages its proprietary technology platforms to manufacture novel drug formulations that are intended to demonstrate improved properties in comparison with current alternatives, which can lead to a reduced side-effect profile and an expanded therapeutic area. The company has a portfolio of projects targeting cancer treatments.

26GF Score

Get the complete analysis for OASMY

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00

Price

View OASMY Analysis

See Research & Development data for all stocks →